- ANI Pharmaceuticals specializes in developing and commercializing generic and branded pharmaceuticals, with a strong focus on rare diseases, and aims to achieve sustainable growth through its diverse business segments.
- In April 2026, ANI announced the FDA approval and launch of Pimozide Tablets, a generic version of Orap®, which comes with 180 days of CGT exclusivity, enhancing its product portfolio.
- The company reported significant growth in its Rare Disease business, with Purified Cortrophin® Gel generating net revenues of $347.8 million in 2025, reflecting a 76% increase year-over-year.
- ANI's ideal buyers include healthcare providers and institutions focusing on rare diseases, as they offer innovative solutions that address unmet medical needs, making them a compelling partner for sales teams targeting this niche market.
Sales and Support is the largest group with 106 employees (about 36%), indicating a substantial go-to-market presence. Finance and Administration totals 33, while Engineering and Operations each have 28 employees, forming a balanced technical and operational core. Marketing and Product (24) and Business Management (21) contribute to strategy and execution, with Quality (16) and Healthcare roles (15) aligned to regulated-industry needs. Human Resources (7) and Other roles (17) round out the staff mix.
The workforce is broadly distributed, with approximately two-thirds (195 employees) categorized under Other locations. Baudette, MN is the largest named hub with 48 employees. Additional presence includes New York, NY (12), Atlanta, GA (8), Princeton, NJ (7), Hightstown, NJ (7), Chicago, IL (6), Philadelphia, PA (6), and smaller teams in Madison, WI (3) and Minneapolis, MN (3). This footprint reflects a combination of hub sites and dispersed teams across the U.S.
